Vnitr Lek 2016, 62(Suppl 3):115-120

Thyroid carcinomas - current therapeutic procedures

Petr Vlček*, Dana Nováková
Klinika nukleární medicíny a endokrinologie 2. LF UK a FN v Motole, Praha

Incidence of differentiated thyroid carcinomas, especially papillary carcinomas, in recent decades worldwide increase. This is especially the detection of small tumor sizes up to two centimeters. Causes of the increase of these cancers are either increased number of thyroid investigations, but also the actual increase of this disease. The subject of expert discussion on this topic is mainly assessment of the severity of newly diagnosed tumors, the choice of treatment strategy and choice of follow-up of patients. Given that a large part of tumor detected in an early stage and due to the success of the current treatment options for the prognosis of thyroid cancer is usually good. Despite the large increase of the incidence, mortality for this type of cancer, in countries with good individualized treatment, decreases. We present a review of literature on the topic.

Keywords: thyroid carcinoma; post-operation monitoring; radioiodine; stratification of the risk of relapse

Received: August 30, 2016; Accepted: September 15, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlček P, Nováková D. Thyroid carcinomas - current therapeutic procedures. Vnitr Lek. 2016;62(Supplementum 3):115-120.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barney BM, Hitchcock YJ, Sharma P et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 2011; 33(5): 645-649. Dostupné z DOI: <http://dx.doi.org/10.1002/hed.21504>. Go to original source... Go to PubMed...
    2. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005; 1(1): 32-40. Go to original source... Go to PubMed...
    3. Blumhardt R, Wolin EA, Phillips WT et al. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review. Endocr Relat Cancer 2014; 21(6): R473-R484. Dostupné z DOI: <http://dx.doi.org/10.1530/ERC-14-0286>. Go to original source... Go to PubMed...
    4. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016; pii: S0140-6736(16)30172-6. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(16)30172-6>. Go to original source... Go to PubMed...
    5. Castagna MG, Maino F, Cipri C et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011; 165(3): 441-446. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-11-0466>. Go to original source... Go to PubMed...
    6. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2009; 19(11): 1159-1165. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2009.0274>. Go to original source... Go to PubMed...
    7. Clement SC, Peeters RP, Ronckers CM et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma - a systematic review. Cancer Treat Rev 2015; 41(10): 925-934. Go to original source... Go to PubMed...
    8. Durante C, Montesano T, Torlontano M et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab 2013; 98(2): 636-642. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012-3401>. Go to original source... Go to PubMed...
    9. Hauch A, Al-Qurayshi Z, Randolph G et al. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 2014; 21(12): 3844-3852. Dostupné z DOI: <http://dx.doi.org/10.1245/s10434-014-3846-8>. Go to original source... Go to PubMed...
    10. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26(1): 1-133. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2015.0020>. Go to original source... Go to PubMed...
    11. Jonklaas J, Sarlis NJ, Litofsky D et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16(12): 1229-1242. Go to original source... Go to PubMed...
    12. Lee TJ, Kim S, Cho HJ et al. The incidence of thyroid cancer is affected by the characteristics of a healthcare system. J Korean Med Sci 2012; 27(12): 1491-1498. Dostupné z DOI: <http://dx.doi.org/10.3346/jkms.2012.27.12.1491>. Go to original source... Go to PubMed...
    13. Lubitz CC, Sosa JA. The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. Cancer 2016 Aug 12. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.30201>. Go to original source... Go to PubMed...
    14. Matsuzu K, Sugino K, Masudo K et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 2014; 38(1): 68-79. Dostupné z DOI: <http://dx.doi.org/10.1007/s00268-013-2224-1>. Go to original source... Go to PubMed...
    15. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86(4): 1447-1463. Go to original source... Go to PubMed...
    16. Mendelsohn AH, Elashoff DA, Abemayor E et al. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg 2010; 136(11): 1055-1061. Dostupné z DOI: <http://dx.doi.org/10.1001/archoto.2010.181>. Go to original source... Go to PubMed...
    17. Nixon IJ, Ganly I, Patel SG et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012; 151(4): 571-579. Dostupné z DOI: <http://dx.doi.org/10.1016/j.surg.2011.08.016>. Go to original source... Go to PubMed...
    18. Orlov S, Orlov D, Shaytzag M et al. Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 2009; 31(6): 782-788. Dostupné z DOI: <http://dx.doi.org/10.1002/hed.21020>. Go to original source... Go to PubMed...
    19. Pacini F, Molinaro E, Castagna MG et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88(3): 3668-3673. Go to original source... Go to PubMed...
    20. Pellegriti G, Frasca F, Regalbuto C et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013; 2013: 96521. Dostupné z DOI: <http://dx.doi.org/10.1155/2013/965212>. Go to original source... Go to PubMed...
    21. Sykorova V, Dvorakova S, Ryska A et al. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 2010; 33(5): 318-324. Dostupné z DOI: <http://dx.doi.org/10.3275/6722>. Go to original source... Go to PubMed...
    22. Torlontano M, Crocetti U, D'Aloiso L et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 2003; 148(1): 19-24. Go to original source... Go to PubMed...
    23. Tuttle RM, Tala H, Shah J et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20(12): 1341-1349. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2010.0178>. Go to original source... Go to PubMed...
    24. Vaclavikova E, Halkova T, Kodetova D et al. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing. Anticancer Res 2015; 35(4): 2029-2036.
    25. Vaccarella S, Franceschi S, Bray F et al. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med 2016; 375(7): 614-617. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMp1604412>. Go to original source... Go to PubMed...
    26. Van den Bruel A, Francart J, Dubois C et al. Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management. J Clin Endocrinol Metab 2013; 98(19): 4063-4071. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-1705>. Go to original source... Go to PubMed...
    27. Vlček P, Nováková D, Vejvalka J et al. Draft of the best medical treatment in patients with low-risk thyroid cancer. Vnitř Lék 2015; 61(9): 769-777. Go to PubMed...
    28. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102(9): 605-613. Dostupné z DOI: <http://dx.doi.org/10.1093/jnci/djq099>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.